financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Reiterates Strong Buy Opinion On Shares Of Visteon Corporation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Reiterates Strong Buy Opinion On Shares Of Visteon Corporation
Apr 25, 2024 6:47 AM

09:20 AM EDT, 04/25/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month target by $10 to $140 on a '25 P/E of 14.0x, a steep but justified discount to VC's 10-year mean forward P/E of 36.3x. We lower our adjusted EPS estimates to $8.25 from $8.60 for '24 and to $10.00 from $10.35 for '25. VC posted Q1 adjusted EPS of $1.61 vs. $1.25 (+29%), short of the $1.68 consensus. The miss was driven by weaker-than-expected sales, as revenue fell 3.5% to $933M ($40M below consensus) and adjusted EBITDA margin expanded 70 bps to 10.9% (10 bps ahead of consensus). VC maintained its full-year sales and adjusted EBITDA guidance of $4.0B-$4.2B and $470M-$500M, respectively, which compares to the current consensus of $4.1B and $482M, respectively. With $7.2B in new business wins in 2023 (up from $6B in 2022) and one of the strongest growth outlooks of any auto supplier, VC remains one of our top picks. After an 11% YTD decline, VC is trading at a steep discount to its historic average P/E and a modest rebound in its multiple implies significant upside from current levels.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Keeps Buy Opinion On Shares Of Edwards Lifesciences Corporation
Research Alert: CFRA Keeps Buy Opinion On Shares Of Edwards Lifesciences Corporation
Oct 31, 2025
11:40 AM EDT, 10/31/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our 12-month target price to $100 from $93, 35x our 2026 EPS and a slight premium to the company's long-term average forward P/E. We lift our 2025 EPS...
Research Alert: CFRA Maintains Hold Opinion On Shares Of Southern Copper Corporation
Research Alert: CFRA Maintains Hold Opinion On Shares Of Southern Copper Corporation
Oct 31, 2025
11:10 AM EDT, 10/31/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We increase our 12-month target price by $55 to $151, driven by an EV/EBITDA multiple of 14.5x applied to our 2027 EBITDA estimate, which is a premium to SCCO's three-year...
Research Alert: CFRA Maintains Sell Opinion On Shares Of Edison International
Research Alert: CFRA Maintains Sell Opinion On Shares Of Edison International
Oct 31, 2025
11:30 AM EDT, 10/31/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: Our 12-month target remains $48, 7.8x our 2026 EPS estimate (down $0.05 to $6.08; 2025 estimate remains $6.03), a wide discount to peers based on weaker growth expectations vs. peers...
Research Alert: CFRA Keeps Hold Opinion On Shares Of Dexcom, Inc.
Research Alert: CFRA Keeps Hold Opinion On Shares Of Dexcom, Inc.
Oct 31, 2025
11:35 AM EDT, 10/31/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We cut our 12-month target to $77 from $89, about 32x our 2026 EPS, below DXCM's average forward P/E and slightly under MedTech peers. We lift our 2025 EPS by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved